Tumor Suppressor Neurofibromin Interacts with Estrogen Receptor, Revealing Potential Combo Breast Cancer Therapy

Tumor Suppressor Neurofibromin Interacts with Estrogen Receptor, Revealing Potential Combo Breast Cancer Therapy
A tumor suppressor protein called neurofibromin, known to block the cancer-inducing Ras pathway, also was found to interact directly with the estrogen receptor (ER) with mutations in this protein leading to treatment resistance in ER-positive breast cancers, a study has revealed. Specifically, cancers lacking a functional neurofibromin protein are resistant to a class of breast cancer therapies that inhibit estrogen synthesis — collectively called aromatase inhibitors — and to tamoxifenA combination of treatments that block both the ER and the Ras signaling pathways is a promising approach for such ER-positive breast cancers. The study, “Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer,” was published in the journal
Subscribe or to access all post and page content.